PKB/Akt Activation and Cell Survival with HIV-1 Tat

HIV-1 Tat 的 PKB/Akt 激活和细胞存活

基本信息

  • 批准号:
    7052884
  • 负责人:
  • 金额:
    $ 12.6万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-04-12 至 2007-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): No convincing explanation exists for the aggressive growth of Kaposi's sarcoma (KS) in the estimated 8 million people worldwide afflicted with both this disease and human immunodeficiency virus type 1 (HIV-1). Human herpesvirus 8 (HHV-8) is required for the development of KS but is insufficient to cause it unless a second factor, such as HIV-1, is present. The HIV-1 transactivator of transcription (Tat) protein is implicated in KS because it stimulates the invasive and proliferative properties of KS cells and endothelial cells (ECs) in cultures and in tat transgenic mice. In preliminary studies, we found that Tat activates phosphatidylinositol 3'-kinase (PI3K) and Akt, the latter is a key regulator in tumorigenesis and cell survival. We found that immobilized Tat and physiologic levels of Tat in solution promoted the survival of KS SLK cells. It is not known how Tat promotes cell survival or to what extent this effect promotes growth of KS. We hypothesize that HIV-1 Tat activates Akt and promotes cell survival. Our preliminary studies with Tat and our exclusive faf transgenic mice lines will enable us to evaluate Tat's role in PI3K-Akt activation and cell survival. Specific Aim 1. Determine to what extent Tat activates Akt In vitro, and identify the signaling pathway Tat uses to promote cell survival. We will characterize Tat-related Akt phosphorylation and Akt kirtase activity in HHV-8 infected dermal microvasculature endothelial (HHV8-OMVE) cells. We will map the active moiety in Tat by using peptides, truncated Tat mutants, and antibodies. We will target the PI3K-Akt pathway with drugs (LY294002 and Perifosine) and PI3K-AM dominant-negative mutants to determine the role of this pathway in Tat-related cell survival. Specific Aim 2. Determine to what extent Tat activates Akt In vivo and promotes tumor growth by analyzing Tatexpressing cells In nude mice and tat transgenic mice. Tat of different sizes will be expressed and mapped on Tat domains critical to Akt phosphorylation. We will also test designed PISK-Akt inhibitors (LY294002 and Perifosine) and candidate anticancer agents for their role in blocking this pathway and reversing tumor growth. Successful completion of these studies will help identify a novel property of Tat that stimulates a survival mechanism anticipated to play a major role in KS and HHV8-DMVE cells. This research plan will establish the potential of drugs designed to interrupt this pathway implicated in KS and perhaps in other cancers associated with HIV-1 infection.
描述(由申请人提供):

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma.
  • DOI:
    10.1038/leu.2014.126
  • 发表时间:
    2014-12
  • 期刊:
  • 影响因子:
    11.4
  • 作者:
    Sehgal L;Mathur R;Braun FK;Wise JF;Berkova Z;Neelapu S;Kwak LW;Samaniego F
  • 通讯作者:
    Samaniego F
Targeting nucleolin for better survival in diffuse large B-cell lymphoma.
  • DOI:
    10.1038/leu.2017.215
  • 发表时间:
    2018-03
  • 期刊:
  • 影响因子:
    11.4
  • 作者:
    Jain N;Zhu H;Khashab T;Ye Q;George B;Mathur R;Singh RK;Berkova Z;Wise JF;Braun FK;Wang X;Patel K;Xu-Monette ZY;Courty J;Young KH;Sehgal L;Samaniego F
  • 通讯作者:
    Samaniego F
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

FELIPE SAMANIEGO其他文献

FELIPE SAMANIEGO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('FELIPE SAMANIEGO', 18)}}的其他基金

Cancer Cell Overexpression of Death Receptor Modulator
癌细胞过度表达死亡受体调节剂
  • 批准号:
    8388622
  • 财政年份:
    2012
  • 资助金额:
    $ 12.6万
  • 项目类别:
Cancer Cell Overexpression of Death Receptor Modulator
癌细胞过度表达死亡受体调节剂
  • 批准号:
    8534726
  • 财政年份:
    2012
  • 资助金额:
    $ 12.6万
  • 项目类别:
Preservation of liver function through modulation of Fas-binding proteins
通过调节 Fas 结合蛋白来保护肝功能
  • 批准号:
    8095442
  • 财政年份:
    2011
  • 资助金额:
    $ 12.6万
  • 项目类别:
Preservation of liver function through modulation of Fas-binding proteins
通过调节 Fas 结合蛋白来保护肝功能
  • 批准号:
    8333368
  • 财政年份:
    2011
  • 资助金额:
    $ 12.6万
  • 项目类别:
PMLRARalpha and PML directly regulate Fas-mediated apoptosis in vivo
PMLRARα 和 PML 直接调节体内 Fas 介导的细胞凋亡
  • 批准号:
    8100046
  • 财政年份:
    2011
  • 资助金额:
    $ 12.6万
  • 项目类别:
Preservation of liver function through modulation of Fas-binding proteins
通过调节 Fas 结合蛋白来保护肝功能
  • 批准号:
    8510636
  • 财政年份:
    2011
  • 资助金额:
    $ 12.6万
  • 项目类别:
PMLRARalpha and PML directly regulate Fas-mediated apoptosis in vivo
PMLRARα 和 PML 直接调节体内 Fas 介导的细胞凋亡
  • 批准号:
    8245030
  • 财政年份:
    2011
  • 资助金额:
    $ 12.6万
  • 项目类别:
Targeting Fas Inhibitors in Cancer Therapy
癌症治疗中的靶向 Fas 抑制剂
  • 批准号:
    8111086
  • 财政年份:
    2010
  • 资助金额:
    $ 12.6万
  • 项目类别:
Targeting Fas Inhibitors in Cancer Therapy
癌症治疗中的靶向 Fas 抑制剂
  • 批准号:
    7994053
  • 财政年份:
    2010
  • 资助金额:
    $ 12.6万
  • 项目类别:
PKB/Akt Activation and Cell Survival with HIV-1 Tat
HIV-1 Tat 的 PKB/Akt 激活和细胞存活
  • 批准号:
    6947584
  • 财政年份:
    2005
  • 资助金额:
    $ 12.6万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了